In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury.

Q1 Biochemistry, Genetics and Molecular Biology
Clinical Biochemist Reviews Pub Date : 2013-11-01
Danilo C de Almeida, Cassiano Donizetti-Oliveira, Priscilla Barbosa-Costa, Clarice St Origassa, Niels Os Câmara
{"title":"In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury.","authors":"Danilo C de Almeida,&nbsp;Cassiano Donizetti-Oliveira,&nbsp;Priscilla Barbosa-Costa,&nbsp;Clarice St Origassa,&nbsp;Niels Os Câmara","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Acute kidney injury (AKI) is classically described as a rapid loss of kidney function. AKI affects more than 15% of all hospital admissions and is associated with elevated mortality rates. Although many advances have occurred, intermittent or continuous renal replacement therapies are still considered the best options for reversing mild and severe AKI syndrome. For this reason, it is essential that innovative and effective therapies, without side effects and complications, be developed to treat AKI and the end-stages of renal disease. Mesenchymal stem cell (MSC) based therapies have numerous advantages in helping to repair inflamed and damaged tissues and are being considered as a new alternative for treating kidney injuries. Numerous experimental models have shown that MSCs can act via differentiation-independent mechanisms to help renal recovery. Essentially, MSCs can secrete a pool of cytokines, growth factors and chemokines, express enzymes, interact via cell-to-cell contacts and release bioagents such as microvesicles to orchestrate renal protection. In this review, we propose seven distinct properties of MSCs which explain how renoprotection may be conferred: 1) anti-inflammatory; 2) pro-angiogenic; 3) stimulation of endogenous progenitor cells; 4) anti-apoptotic; 5) anti-fibrotic; 6) anti-oxidant; and 7) promotion of cellular reprogramming. In this context, these mechanisms, either individually or synergically, could induce renal protection and functional recovery. This review summarises the most important effects and benefits associated with MSC-based therapies in experimental renal disease models and attempts to clarify the mechanisms behind the MSC-related renoprotection. MSCs may prove to be an effective, innovative and affordable treatment for moderate and severe AKI. However, more studies need to be performed to provide a more comprehensive global understanding of MSC-related therapies and to ensure their safety for future clinical applications. </p>","PeriodicalId":34924,"journal":{"name":"Clinical Biochemist Reviews","volume":"34 3","pages":"131-44"},"PeriodicalIF":0.0000,"publicationDate":"2013-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866950/pdf/cbr-34-131.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Biochemist Reviews","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Acute kidney injury (AKI) is classically described as a rapid loss of kidney function. AKI affects more than 15% of all hospital admissions and is associated with elevated mortality rates. Although many advances have occurred, intermittent or continuous renal replacement therapies are still considered the best options for reversing mild and severe AKI syndrome. For this reason, it is essential that innovative and effective therapies, without side effects and complications, be developed to treat AKI and the end-stages of renal disease. Mesenchymal stem cell (MSC) based therapies have numerous advantages in helping to repair inflamed and damaged tissues and are being considered as a new alternative for treating kidney injuries. Numerous experimental models have shown that MSCs can act via differentiation-independent mechanisms to help renal recovery. Essentially, MSCs can secrete a pool of cytokines, growth factors and chemokines, express enzymes, interact via cell-to-cell contacts and release bioagents such as microvesicles to orchestrate renal protection. In this review, we propose seven distinct properties of MSCs which explain how renoprotection may be conferred: 1) anti-inflammatory; 2) pro-angiogenic; 3) stimulation of endogenous progenitor cells; 4) anti-apoptotic; 5) anti-fibrotic; 6) anti-oxidant; and 7) promotion of cellular reprogramming. In this context, these mechanisms, either individually or synergically, could induce renal protection and functional recovery. This review summarises the most important effects and benefits associated with MSC-based therapies in experimental renal disease models and attempts to clarify the mechanisms behind the MSC-related renoprotection. MSCs may prove to be an effective, innovative and affordable treatment for moderate and severe AKI. However, more studies need to be performed to provide a more comprehensive global understanding of MSC-related therapies and to ensure their safety for future clinical applications.

Abstract Image

寻找急性肾损伤间充质干细胞治疗的相关机制。
急性肾损伤(AKI)通常被描述为肾功能的快速丧失。AKI影响了所有住院患者的15%以上,并与死亡率升高有关。虽然已经取得了许多进展,但间歇性或持续的肾脏替代疗法仍然被认为是逆转轻度和重度AKI综合征的最佳选择。因此,必须开发无副作用和并发症的创新和有效的疗法来治疗AKI和终末期肾脏疾病。基于间充质干细胞(MSC)的治疗方法在帮助修复炎症和受损组织方面具有许多优势,正被认为是治疗肾损伤的新选择。许多实验模型表明,间充质干细胞可以通过不依赖于分化的机制来帮助肾脏恢复。从本质上讲,间充质干细胞可以分泌一系列细胞因子、生长因子和趋化因子,表达酶,通过细胞间接触相互作用,并释放生物制剂(如微泡)来协调肾脏保护。在这篇综述中,我们提出了MSCs的七个不同特性,这些特性解释了如何赋予肾保护作用:1)抗炎;2) pro-angiogenic;3)内源性祖细胞的刺激;4)抗凋亡;5) anti-fibrotic;6)抗氧化;7)促进细胞重编程。在这种情况下,这些机制,无论是单独的还是协同的,都可以诱导肾脏保护和功能恢复。这篇综述总结了在实验性肾脏疾病模型中与msc为基础的治疗相关的最重要的作用和益处,并试图阐明msc相关肾保护的机制。MSCs可能被证明是一种有效、创新和负担得起的治疗中、重度AKI的方法。然而,需要进行更多的研究,以提供对msc相关疗法更全面的全球了解,并确保其在未来临床应用中的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Biochemist Reviews
Clinical Biochemist Reviews Biochemistry, Genetics and Molecular Biology-Clinical Biochemistry
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信